Quote:
Originally Posted by 1990nyboy
The FDA was not convinced in 2011 by Teva's ADAGIO trial. Results were very odd and difficult to explain. E.g., whereas 1 mg showed some neuroprotection 2 mg show none at all.
|
Teva doesn't say it could not be neuroprotective. It only stated that given the results one could not be 100 % sure to make this claim.
Quote:
Originally Posted by 1990nyboy
It is hard to account for this kind of finding. Why would there not be a dose-response effect?
|
Azilect gives symptomatic benefits. A 2 mg dose would give better symptomatic benefits which could be why the delay group has the same score as the non-delay group.
Quote:
Originally Posted by 1990nyboy
There are a variety of new, potentially effective neuroprotective agents being tested. I wouldn't bet the farm on Azilect.
Howard
|
Which are those agents ?